Chronic oral anticoagulant therapy is recommended (class I) in patients with mechanical heart valves and in patients with atrial fibrillation with a CHA 2 DS 2 -VASc (Congestive heart failure, Hypertension, Age $75 years, Diabetes mellitus, prior Stroke or transient ischemic attack or thromboembolism, Vascular disease, Age 65 to 74 years, Sex category) score $1.
In a rapidly aging population, the number of patients experiencing both AF and CAD is steadily increasing. However, triple therapy produces a high annual bleeding risk of up to 45%, and an association has been seen among major bleeding events, blood transfusion, and increased mortality risk (6-11). Triple therapy, including vitamin K antagonists (VKAs), After the WOEST trial results were published, expert opinion was that it was too early to change the guidelines, even though current recommendations are not based on randomized trials (23). The reasons given for the reluctance to change guidelines were based on the limitations of the WOEST trial. First, the number of patients randomized was relatively low (n ¼ 573) and not every patient had AF (approximately 70%). Second, there was no significant difference in TIMI major bleeding, and the absolute number of major bleeds was rather low (16 vs. 9). The difference in bleeding was mainly driven by TIMI minor bleeding. However, when bleeding events were classified according to the new standardized BARC bleeding criteria, there was a significant difference in BARC 3 bleeding, which corresponds with major bleeding, in favor of the combination of clopidogrel and VKA (6,22). Additionally, the authors emphasized the importance of minor bleeding, because these events can lead to cessation of medication (e.g., clopidogrel) and major adverse events such as stent thrombosis (6). Third, compared with current recommendations, the rate of proton pump Dewilde et al.
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Triple Therapy for AF and PCI inhibitor (PPI) use at baseline was low (37%), the radial approach was used infrequently (26%), baremetal stents (BMS) were used in a minority of patients (31%), periprocedural target INR was 2.0, and the long-term target INR was not lowered postprocedurally (target INR 2 to 3 for AF). These results are compared with current guidelines, which recommend standard PPI use, radial approach, BMS use, and a lower long-term target INR of 2 to 2.5 in this patient population. The conflict with the guidelines is easily explained: in 2008, when the WOEST study was designed, these recommendations were not available yet (4,12). Fourth, the number of deaths was significantly higher with triple therapy, but this was driven by a higher number of noncardiac deaths, which might be due to a play of chance. Fifth, there was no information on the time of INR in the therapeutic range.
However, we know from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy)
trial that the quality of oral anticoagulation is good in the Netherlands and Belgium, with a therapeutic range of 65% for patients treated in Belgium and up to 70% in the Netherlands (24). Finally, the study was not powered to show noninferiority of the secondary outcomes and the number of patients at high risk of stent thrombosis, such as those with recent ACS, was limited to a quarter of the WOEST trial participants.
The study population was heterogeneous, because the goal was to conduct a trial with a real-life population representing daily practice (6). Moreover, the Therefore, the impact of bleeding could be even larger in real life than reported in these studies. This could also explain why the bleeding rate reported in the WOEST trial stood very high compared to other trials, as this study was specifically designed to detect bleeding events and data were collected for all types of bleeding rather than solely focusing on major bleeding events (6).
Another issue that needs to be addressed: patients with AF in need of PCI represent a population that mainly consists of older patients with high rates of comorbidity. Many are octogenarians, a group frequently excluded from or under-represented in randomized clinical trials. It is questionable whether our current guidelines can be applied to this group.
Additionally, we know that older patients with AF have a higher CHA 2 DS 2 -VASc score as well as a higher bleeding risk when treated with VKAs (37). In this population, the role of nonmajor bleeding should not be underestimated. Even superficial or "nuisance" bleeding can lead to discontinuation of antiplatelet therapy, which can lead to subsequent thrombotic complications, such as stent thrombosis. Clearly, this high-risk population, often with multiple comorbidities, is more prone to experience treatment-related adverse events (4,38).
Over the last years, numerous risk factors have been associated with higher bleeding risk: age >55 years, female sex, glomerular filtration rate <60 ml/min, pre-existing anemia, use of low-molecularweight heparin (LMWH) <48 h before PCI, use of glycoprotein IIb/IIIa inhibitors, and the use of an intra-aortic balloon pump (27,39,40).
To estimate bleeding risk, many bleeding riskprediction scores have been proposed, and the best known is the HAS-BLED score (41) . The HAS BLED score estimates the risk for major bleeding for patients on anticoagulation and is based on the presence of some high-risk features as hypertension, stroke, renal disease, liver disease, prior major bleeding, age older than 65 years, labile INR, the use of medication predisposing to bleeding and weekly alcohol usage.
Shown to be useful in the assessment of bleeding risk, the HAS-BLED score also demonstrates some predic- The fifth dilemma focuses on how to overcome the possibility of unopposed thromboxane-dependent platelet activation after stopping aspirin with subsequent cardiovascular events (63) . In 2 patient series in which aspirin monotherapy was stopped without a substitute, higher rates of thrombotic events occurred (64, 65) . Of course, a patient group on aspirin monotherapy totally differs from the present patients receiving long-term VKA plus clopidogrel therapy.
Nevertheless, in the WOEST trial, the AFCAS trial, and the Danish and German registries, there was no excess of stent thrombosis in the aspirin-free group (6,13-15). Therefore, it is debatable whether this Dewilde et al. Dewilde et al. Dewilde et al. 
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